Dr. Joan Lau has more than 20 years of executive leadership experience, including as chief executive officer, chief operating officer, trustee, and non-executive director. In 2016, she co-founded Talee Bio, renamed Spirovant after its acquisition, a company focused on discovery and development of gene therapies for respiratory diseases, and serves as its Chief Executive Officer. In 2013, she co-founded and became a partner of Militia Hill Ventures, which creates and builds innovative life science entities.
A recognized leader in the Philadelphia community and biopharma industry, Dr. Lau serves on the boards of trustees for the Philadelphia Orchestra and Kimmel Center; the University of Pennsylvania; Brandywine Realty Trust; RiboNova; and Rockwell Medical and served on the board of directors of Renovacor until its acquisition by Rocket Pharmaceuticals. She has been recognized as a Philadelphia Entrepreneur of Year by Ernst & Young and as a Woman of Distinction by the Philadelphia Business Journal.
It’s time to build the infrastructure needed to scale up inhaled gene therapies targeting cystic fibrosis, and to bolster investment that supports several key program components.